<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809600</url>
  </required_header>
  <id_info>
    <org_study_id>CISL-1203</org_study_id>
    <nct_id>NCT01809600</nct_id>
  </id_info>
  <brief_title>Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults</brief_title>
  <acronym>RBL</acronym>
  <official_title>Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective study is aimed at evaluating the safety and efficacy of
      rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or
      high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large
      B-cell lymphoma and BL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria

        1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria

        2. age &gt;20 yrs

        3. received rituximab+chemotherapy as first-line treatment

        4. with measurable or evaluable lesion

        5. with complete set of clinical and laboratory data for the analysis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>one year</time_frame>
    <description>Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>1-year</time_frame>
    <description>treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1-year</time_frame>
    <description>Overall survival is defined as the time from treatment initiation until death as a result of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 4 hematologic toxicities</measure>
    <time_frame>one year</time_frame>
    <description>toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Burkitt's Lymphoma</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Patients with Burkitt's Lymphoma</arm_group_label>
    <description>should be diagnosed pathologically by WHO 2008 criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention (observational study)</intervention_name>
    <arm_group_label>Patients with Burkitt's Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who were treated with Burkitt's or Burkitt-like high-grade B-cell lymphoma in
        Republic of Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma,
             unclassifiable, with features intermediate between diffuse large B-cell lymphoma and
             BL (BL-U) by WHO 2008 criteria

          2. age &gt;20 yrs

          3. received rituximab+chemotherapy as first-line treatment

          4. with measurable or evaluable lesion

        Exclusion Criteria:

        1. patients with BL or BL-U previously treated with rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk Jin Kim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Junshik Hong</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

